LL-37 PEPTIDE · THE ESSENTIALS
Skin defends itself.
Then it needs to repair.
LL-37 participates in both processes. Interest in this peptide comes from the link between microbial defence and the cells that close a wound. Research has reached clinical trials, but a treatment benefit for general use has not been established.
37 amino acids, produced by the body.
The name describes part of its structure: LL refers to the two starting leucines, while 37 is its amino-acid count. The peptide is released from a larger protein, hCAP18. It occurs in skin and in innate immunity, the defence that responds quickly to a threat. ↗
In trials, synthetic LL-37 was applied directly to persistent venous ulcers. This addresses a specific question: can it add to medical care for a hard-to-heal wound? That is different from using an injectable vial for “immunity”.
37 dots = 37 amino acids.
A counting diagram, not a 3D molecular structure.
Defence
Interactions with microbes, studied in the laboratory.
Repair
Skin cells, small vessels and trials in venous ulcers.
Context
Effects vary with tissue and disease.
MECHANISM · EXPLAINED SIMPLY
From an injury
to rebuilding the barrier.
A wound does not close through a single process. Cells need to move, local defence needs to work and tissue needs a blood supply. LL-37 can influence several of these steps.
The wound first needs protection.
When the skin barrier is broken, tissue encounters microbes and produces defence signals. LL-37 is part of this natural response. In healing human skin, the peptide has been found in areas involved in rebuilding the surface. ↗
Cells at the edges begin to cover the damaged area.
Keratinocytes make up most of the outer skin layer. In the laboratory, LL-37 stimulated their migration. EGFR was one mechanism studied: blocking this receptor reduced the response in the experiment. ↗
Complete closure is the important test.
Cell movement seen under a microscope does not guarantee closure of a patient’s wound. Circulation, infection and underlying disease also matter. The larger clinical trial therefore assessed complete ulcer closure, confirmed and maintained for two weeks. ↗
Explanatory schematic. Movement and distances do not represent healing speed or a personal outcome.
CLINICAL TRIALS · TOPICAL USE
What happened
when it was tested in people?
Venous ulcers can remain open for a long time. LL-37 was tested as an additional topical treatment alongside wound care and compression. The two trials need to be read together.
2014 · An encouraging start
In a study of 34 patients with four weeks of treatment, the lower topical concentration improved a measure of healing rate. The highest concentration provided no advantage. The sample was too small for general conclusions; the result justified a larger trial. ↗
2021 · The larger test
HEAL LL-37 included 149 randomized participants, 148 treated and 144 in the main analysis. Treatment lasted 13 weeks. Confirmed complete ulcer closure was similar across the three groups. The trial did not demonstrate a significant benefit on its primary endpoint. ↗
Completely closed ulcers · estimated proportion, %
No statistically significant advantage over placebo.
Completely closed ulcers · estimated proportion, %
Exploratory result. Confirmation in a new trial is needed.
HEAL LL-37 · 13 weeks · topical application with medical compression in every group. Source: Table 4. Percentages are published statistical estimates, not simple divisions of wound counts by patient counts. Concentrations identify study arms, not directions for use. ↗
Why does the second chart not change the overall conclusion?
Separating large ulcers was a post-hoc analysis. The trial was not sized to confirm efficacy in these small groups. Across the full population, comparisons with placebo gave p = 0.4453 and p = 0.5274. In large ulcers, the lower concentration gave p = 0.0458; that generates a hypothesis rather than replacing the primary result.
The study was funded by Promore Pharma AB, with commercial interests declared for some authors. Post-treatment follow-up was disrupted by the pandemic: only 63.5% attended at least one follow-up visit.
MICROBES & BIOFILM
Why is it called
an antimicrobial peptide?
LL-37 can interact with certain microorganisms. Affecting a bacterium in the laboratory and treating an infection in a patient are different stages of research.
Biofilm, explained simply
Some bacteria gather on surfaces and form a community within a protective coating. This is a biofilm. Overhage studied Pseudomonas aeruginosa and showed that LL-37 can alter formation of this layer under laboratory conditions. ↗
Why this does not mean “clears any infection”
A real wound contains fluids, proteins, other microorganisms and damaged tissue. These change how a substance reaches its target and works. The studies presented do not establish LL-37 injections as treatment for fungal infection, Lyme disease or biofilm in the body.
SMALL VESSELS · PRECLINICAL RESEARCH
A wound also needs
a good blood supply.
Cells repairing tissue need oxygen and nutrients. Formation of new small vessels is one area explored in LL-37 research.
What researchers observed
Koczulla and colleagues studied endothelial cells, which line vessels, and animal models. LL-37 influenced cell movement and growth and vessel formation. This process is called angiogenesis. ↗
What it means for healing
It provides a biological reason to study local repair. It does not establish treatment of venous insufficiency, artery repair or improved circulation throughout the body. Medical compression remained part of care in the ulcer trials. ↗
SKIN & IMMUNITY
The same family of molecules.
Different effects in skin.
LL-37 does not act in just one direction. Its effects depend on processing, surrounding cells and the disease being studied.
Atopic dermatitis
Researchers found lower levels of some antimicrobial peptides in atopic dermatitis lesions than in psoriasis. This is an observation about skin defence; it does not establish that adding LL-37 cures eczema. ↗
Rosacea
Cathelicidin processing is altered in rosacea skin. Some resulting fragments promoted inflammation in experiments. They should not all be equated with intact LL-37, and the study is not a rosacea treatment trial. ↗
Psoriasis
LL-37 can form complexes with self-DNA. In experiments relevant to psoriasis, these activated certain immune cells. “Boosts immunity” therefore does not tell us whether an effect is useful or unwanted in a particular situation. ↗
DERMIS & COLLAGEN
What does it have to do
with wrinkles and scars?
A role in tissue repair is not enough to promise skin rejuvenation. For collagen, the laboratory result is more nuanced than some advertising suggests.
What the study measured
Park and colleagues tested human dermal fibroblasts. Under the experimental conditions, LL-37 reduced type I and III collagen synthesis. This challenges the simplistic idea that the peptide always produces “more collagen”. ↗
What that experiment cannot tell us
Less collagen in a cell culture does not show that a scar will flatten or wrinkles will disappear. Nor does it establish collagen loss in a person’s skin. Those outcomes require clinical studies measuring changes in skin.
PERSONAL EXPERIENCES · REDDIT
What people say
after trying it.
Three accounts from the same discussion, describing different experiences. These are paraphrases, not clinical results. Diagnoses, products and the contribution of each substance have not been medically verified.
An improvement the person says lasted
One person describes a foot-skin problem they regarded as a fungal infection, for which creams had not helped enough. After using LL-37, they say symptoms disappeared and had not returned three months later. A reply clarifies that they used injections, not cream. No tests are presented to confirm the diagnosis or cause of improvement; this experience is not equivalent to the topical ulcer trials.
Read the discussion ↗Less discomfort, without claiming a cure
In the same discussion, another person recalls a period when their gut felt less reactive. Asked how they knew dysbiosis had disappeared, they clarify that they were not claiming this: they were describing how they felt. They also used TA-1. That distinction separates a favourable experience from evidence that a disease was treated.
Read the discussion ↗For someone else, brain fog became worse
After about two weeks, one person reports feeling unwell and having worse brain fog. They mention a doctor-led protocol and the later addition of MOTS-c and SS-31, without an improvement they could notice at the time. The account does not establish the cause. Feeling worse cannot automatically be interpreted as the peptide “working” or the body detoxifying.
Read the discussion ↗SAFETY
Safety and possible
side effects.
The data below come from topical use on venous ulcers under medical supervision. They do not fully describe injection or long-term risks.
| Reported outcome | LL-37 0.5 mg/mL n = 48 | LL-37 1.6 mg/mL n = 49 | Placebo n = 51 |
|---|---|---|---|
| People with at least one adverse event | 20 / 48 | 24 / 49 | 20 / 51 |
| Serious adverse events — event count | 4 | 7 | 1 |
An adverse event is a problem occurring during a study, not necessarily caused by treatment. Assessors did not attribute any of the 12 serious events to the investigational product. Local skin reactions also occurred; most were mild or moderate, without a consistent difference between groups. ↗
Immune response and product quality
FDA flags possible immune reactions and problems involving impurities or peptide characterization in compounded products. Composition and administration route matter. A label does not confirm a product’s identity or sterility. ↗
Signals requiring further research
FDA notes nonclinical findings concerning male reproduction and tumour-promoting effects in some tissues. These are not quantified human risks and do not mean LL-37 automatically causes cancer. They do prevent a conclusion of general safety. ↗
Long-term use and special situations
Evidence is insufficient for pregnancy, breastfeeding, children, interactions and repeated long-term use. New symptoms should not automatically be explained as “detox” or “Herx”. An unpleasant reaction needs assessment rather than an assumption that it proves the peptide works. ↗
A wound with spreading redness, fever, increasing pain or pus needs prompt medical assessment. Breathing difficulty or swelling of the tongue or throat requires emergency medical help.
06 / FAQ
Your questions.
Clear answers.
The dossier, explained simply. Open a question for the answer and its source.
What is the LL-37 peptide?
LL-37 is a human peptide made of 37 amino acids. Released from the protein hCAP18, it participates in natural defence in skin and other tissues. Researchers study its effects on microbes, inflammation and wound repair.
Source & context ↗What might LL-37 help with?
The most direct clinical research presented here concerns topical use on hard-to-heal venous leg ulcers. Laboratory work also explores microbes and skin cells. Human trials produced mixed results, so general wound or infection-healing benefits cannot be promised.
Source & context ↗What did the HEAL LL-37 trial show?
In the analysis of 144 patients, confirmed ulcer closure was estimated at 26.5% and 24.7% in the two LL-37 groups versus 25.3% with placebo. Differences were not statistically significant. All groups also received medical compression; these results concern 13 weeks of topical treatment.
Source & context ↗Why are better results reported for large ulcers?
A later analysis separated ulcers of at least 10 cm² and found a favourable result at the lower concentration. Groups contained only 21–24 patients. This exploratory observation supports further study; it does not confirm that LL-37 heals large ulcers.
Source & context ↗Is LL-37 a natural antibiotic?
It is a natural peptide with antimicrobial activity in experiments. That description does not mean it can replace a prescribed antibiotic. Laboratory effects against bacteria do not establish effectiveness, dose or safety for treating a human infection.
Source & context ↗Does LL-37 eliminate biofilm?
In a laboratory study, LL-37 influenced Pseudomonas aeruginosa biofilm formation. Biofilm is a layer of microorganisms attached to a surface. This does not show that LL-37 injections eliminate biofilm in a wound, the gut or on an implant.
Source & context ↗Does LL-37 help with atopic dermatitis?
Some research found lower antimicrobial peptide levels in atopic dermatitis lesions than in psoriasis lesions. This helps explain disease biology but does not establish LL-37 administration as treatment. Therapeutic recommendations require treatment trials.
Source & context ↗Why does LL-37 appear in rosacea research?
Cathelicidin processing is altered in rosacea, and some fragments can intensify inflammation. A defence peptide therefore should not automatically be considered soothing. This work does not establish LL-37 as a rosacea treatment.
Source & context ↗Does LL-37 boost collagen?
There is no basis for that general promise. In cultured human fibroblasts, LL-37 reduced type I and III collagen synthesis under certain conditions. This also does not establish skin rejuvenation or scar removal in people.
Source & context ↗Can LL-37 calm inflammation throughout the body?
LL-37 modifies immune responses, but its effects depend on tissue and disease. It can participate in both defence and pathways that sustain inflammation, including those studied in psoriasis. It is not a universal anti-inflammatory.
Source & context ↗Do wound trials show that injections are safe?
No. The trials described tested local application to ulcers under controlled medical conditions. Injection changes exposure and risks. Evidence from a topical treatment does not validate self-injection for skin, immunity or infections.
Source & context ↗What adverse events were reported?
In the larger trial, adverse events were reported in 20 of 48, 24 of 49 and 20 of 51 patients in the two LL-37 groups and the placebo group. Not all were caused by treatment. These topical-use data do not fully characterize injection or long-term risks.
Source & context ↗Is there a cancer or infertility risk?
FDA notes nonclinical signals concerning tumour-promoting effects in some tissues and male reproduction. These do not establish such outcomes in people or allow a human risk estimate. They are reasons not to declare systemic use safe.
Source & context ↗If the body makes it, why does it need testing?
The body produces LL-37 in particular locations and conditions. An externally administered product may change concentration, duration and exposed tissues. Natural presence does not establish the safety of a formulation or administration route.
Source & context ↗Is LL-37 an approved wound medicine?
In the reviewed sources, LL-37/ropocamptide is an investigational treatment, not an approved wound-healing medicine. Permission to conduct a trial is not marketing authorization. Online sale does not establish approval or pharmaceutical quality.
Source & context ↗Is LL-37 the same peptide as KPV?
No. LL-37 has 37 amino acids and comes from hCAP18. KPV has three amino acids and occurs in the sequence of a different hormone, α-MSH. Both feature in skin research, but their mechanisms and evidence differ. Findings for one cannot be assigned to the other.
Source & context ↗SOURCES & METHOD
Where the
information comes from.
Editorial review: 15 October 2026. The supplied dossier was supplemented by focused checks of the original clinical paper, European trial registry, FDA information and Reddit discussion.
Charts use estimated proportions from Table 4 of HEAL LL-37. The safety table uses Table 5 and distinguishes people from events. The primary result and exploratory analysis are shown together. Other mechanisms draw on the original studies identified in the supplied dossier; not every paper was independently checked in full.
Reddit accounts were read and paraphrased, retaining context and links. They are not a representative sample of all users. No YouTube comments were included. This is an educational synthesis, not a systematic review.
- Mahlapuu et al. · HEAL LL-37 · 2021 · Tables 4–5 ↗
- Grönberg et al. · LL-37 in venous leg ulcers · 2014 ↗
- EU Clinical Trials Register · HEAL LL-37 results ↗
- Heilborn et al. · LL-37 and re-epithelialization · 2003 ↗
- Tokumaru et al. · Keratinocyte migration and EGFR · 2005 ↗
- Koczulla et al. · Angiogenic role of LL-37 · 2003 ↗
- Overhage et al. · Bacterial biofilm formation · 2008 ↗
- Ong et al. · Antimicrobial peptides in atopic dermatitis · 2002 ↗
- Yamasaki et al. · Cathelicidin and rosacea · 2007 ↗
- Lande et al. · LL-37, self-DNA and immune activation · 2007 ↗
- Park et al. · Collagen synthesis in dermal fibroblasts · 2009 ↗
- FDA · Cathelicidin LL-37 · Compounding safety concerns ↗
- Reddit · LL-37: personal experiences ↗
The conversation continues.